Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock took a round trip from $1.80 to $5.
80 and back. Serious investors should consider buying shares of CytomX Therapeutics. CytomX Therapeutics develops cancer-treatment candidates through the company’s PROBODY therapeutic platform .
This company is trying to save lives and is not a meme or a joke. In fact, CytomX Therapeutics is working diligently with a famous Big Pharma company on a crucial collaboration, so let’s delve into the details right now. CytomX Therapeutics Partners With a Pharma Giant Here’s what you need to know.
CytomX Therapeutics is teaming up with Merck (NYSE: MRK ) on a clinical trial. Together, they’ll assess CytomX Therapeutics’ cytokine, CX-801, in a combination therapy with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), to treat tumors. This is certainly exciting from a medical standpoint.
Wayne Chu, chief medical officer of CytomX Therapeutics, emphasized that this proposed combination therapy is intended to treat “a broad range of tumor types.” Furthermore, CytomX Therapeutics CEO Sean McCarthy proposed that the combination therapy could be a “highly effective regimen to significantly improve the outcomes of patients with cancer.” This could be a game changer and a life changer, since CytomX Therapeutics will have access to Merck’s.
